Mithra Pharmaceuticals (CHIX:MITRAB) Net Income From Continuing Operations : €-38.93 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Mithra Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Mithra Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2023 was €-40.22 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was €-38.93 Mil.

Mithra Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Mithra Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mithra Pharmaceuticals Net Income From Continuing Operations Chart

Mithra Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

35.46

34.97

-83.68

-87.88

-26.25

Mithra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-36.53	-51.34	-27.54	1.29	-40.22

Mithra Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-38.93 Mil.

Mithra Pharmaceuticals (CHIX:MITRAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mithra Pharmaceuticals SA (CHIX:MITRAb) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

0R91:UK 1TM:Germany MITRA:Belgium

Address

Rue Saint-Georges 5, Liege, BEL, 4000

Website

https://www.mithra.com

Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.

Mithra Pharmaceuticals (CHIX:MITRAB) Headlines

No Headlines